ETFS Holding Abbvie Inc

 
ETF Quotes for ETFS Holding Abbvie Inc top ^
  • Holdings: Facebook Inc Class A , AbbVie Inc , Phillips 66 , Kraft Foods Group Inc , General Motors Co ,
  • Morningstar Rating: 5 Stars
Sign-up for fpx investment picks

 
News Articles for Abbvie Inc top ^
2014/12/7
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia - Study Evaluated Preliminary Efficacy of Venetoclax in 32 Patients with Relapsed/Refractory Acute Myelogenous Leukemia and as Frontline Therapy in Patients Unfit for Intensive Treatment NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting investment picks
2014/12/30
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at 33rd Annual J.P. Morgan Healthcare Conference investment picks
2014/12/23
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference investment picks
2014/12/22
By MarketWatch, MarketWatch Energy plays fall again NEW YORK (MarketWatch) -- These stocks are making moves Monday: Gilead Sciences Inc.(GILD) is slumping and AbbVie Inc.(ABBV) is gaining after Express Scripts Holding Co.(ESRX), the largest manager of U.S. prescription-drug benefits, decided an AbbVie drug will be its exclusive option for treating the most common form of hepatitis C.
Sign-up for UPDATE: AbbVie, American Apparel gain; Gilead sinks investment picks
2014/12/22
By MarketWatch, MarketWatch Steelcase to post earnings after Monday's close NEW YORK (MarketWatch) -- These are the stocks that could grab the spotlight Monday, as a holiday-shortened trading week begins: Gilead Sciences Inc.(GILD) is slumping and AbbVie Inc.(ABBV) is gaining after Express Scripts Holding Co.(ESRX) , the largest manager of U.S. prescription-drug benefits, decided an AbbVie drug will be its exclusive option for treating the most common form of hepatitis C.
Sign-up for UPDATE: Gilead, AbbVie, Denbury in focus investment picks
2014/12/22
By Joseph Walker The largest manager of U.S. prescription-drug benefits is taking sides in a fight between new hepatitis C treatments that cost close to $100,000 per patient.
Sign-up for Express Scripts picks AbbVie over Gilead for hepatitis C drug investment picks
2014/12/22
- Viekira Pak® Will Be the Exclusive Option for Genotype 1 Hepatitis C Patients Covered by the Express Scripts National Preferred Formulary - Multi-Year Agreement Significantly Expands Affordable Access to a Curative Hepatitis C Therapy - Superior Patient Care, Greater Payer Value Available Through Accredo® Specialty Pharmacy ST.
Sign-up for Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need investment picks
2014/12/19
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced the U.S. Food and Drug Administration (FDA) has approved AbbVie’s VIEKIRA PAK™ (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) with or without ribavirin for the treatment of genotype 1 (GT1) patients with chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis.
Sign-up for Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus investment picks
2014/12/19
- In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure - Tolerability profile shows more than 98 percent of patients completed a full course of therapy - All-oral interferon-free regimen also approved for HCV/HIV-1 co-infection and patients who have undergone a liver transplant NORTH CHICAGO, Ill.
Sign-up for AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C investment picks
2014/12/19
By Peter Loftus AbbVie's Viekira Pak, a cocktail of several drugs, cured more than 90% of most common form of hepatitis C U.S. regulators on Friday approved AbbVie Inc.'s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.
Sign-up for FDA approves AbbVie's hepatitis treatment investment picks
2015/1/8
AbbVie Inc. (ABBV) on Thursday raised its 2015 earnings outlook and said it will further refine numbers as the launch of its Hepatitis C treatment progresses.
Sign-up for AbbVie raises 2015 outlook investment picks
2015/1/8
- Expects Adjusted Earnings Per Share of $4.25 to $4.45 (GAAP EPS of $3.99 to $4.19); Guidance to be Further Refined as HCV Launch Progresses - Guidance Midpoint Reflects Adjusted EPS Growth of More Than 30 Percent from AbbVie's Previously Communicated 2014 Guidance Range NORTH CHICAGO, Ill.
Sign-up for AbbVie Issues Strong Outlook for 2015 investment picks
2015/1/8
AbbVie Inc. (ABBV) on Thursday announced positive results from a late-stage trial of a treatment for endometriosis.
Sign-up for AbbVie announces positive Phase 3 trial of endometriosis treatment investment picks
2015/1/8
- Study meets co-primary efficacy endpoints; results show treatment with elagolix reduces endometriosis-associated pain (dysmenorrhea and non-menstrual pelvic pain) compared to placebo - Results from the first of two six-month, Phase 3 studies - Full data to be presented at a future date NORTH CHICAGO, Ill.
Sign-up for AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometriosis investment picks
2015/1/12
-- DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson's disease --
Sign-up for AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease investment picks
2015/1/20
The University of Illinois today announced that AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company based in North Chicago, IL, has opened the AbbVie Innovation Center on campus at the University of Illinois Research Park in Urbana-Champaign.
Sign-up for AbbVie Innovation Center Opens at the University of Illinois-Urbana Research Park investment picks
2015/1/16
- DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson's disease - In a clinical trial, patients treated with DUOPA experienced significantly greater improvement in "off" time than patients treated with oral carbidopa-levodopa immediate release tablets NORTH CHICAGO, Ill.
Sign-up for AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease investment picks
2015/1/16
By Michael Calia Combination of Viekirax and Exviera already has U.S. approval AbbVie Inc. (ABBV) said Friday that European regulators approved the sale of the company's hepatitis C treatment.
Sign-up for AbbVie's hepatitis C drug gets European approval for sale investment picks
2015/1/16
Enanta Announces European Commission Grants Marketing Authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Genotypes 1 and 4 Chronic Hepatitis C Virus Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the European Commission has granted marketing authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) 1,2 with or without ribavirin (RBV) for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.
Sign-up for Enanta Announces European Commission Grants Marketing Authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets)... investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

ETFS Holding Abbvie Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Abbott Laboratories  |  Next: ETFS Holding Abengoa SA